Skip to Content

AstraZeneca PLC AZN

Rating as of

Morningstar’s Analysis

Valuation
Currency in GBX
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

AstraZeneca’s Continual Focus on Innovative Drug Development Increasingly Sets Up Strong Growth

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

After a deep dive review of several of AstraZeneca’s current and pipeline products, we have increased our projections for several drugs leading to a fair value estimate increase to $64 from $60. We continue to view the company with a wide moat, supported by a strong pipeline and a relatively secure current portfolio with limited near-term patent losses.

Read Full Analysis

Company Profile

Business Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its revenue.

Contact
1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA, United Kingdom
T +44 2037495000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 76,100

Related